Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249453 | 0.77 | HDAC8 (0.47) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL3218780 | 0.75 | HDAC8 (1.00) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL3218796 | 0.75 | HDAC8 (1.00) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL11727844 | 0.72 | ALDH1A1 (0.54) | LMNAALDH1A1 | |
| SCHEMBL10449499 | 0.69 | HDAC1 (0.67) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL10457552 | 0.69 | HDAC1 (0.67) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL1520861 | 0.67 | ALDH1A1 (0.73) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL6024937 | 0.65 | PTGS2 (0.51) | LMNAALDH1A1 | |
| SCHEMBL12732943 | 0.63 | HDAC8 (0.55) | HDAC1HDAC8HDAC10HDAC4HDAC3 | |
| SCHEMBL29867042 | 0.63 | HDAC8 (0.55) | HDAC1HDAC8HDAC10HDAC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272982-A1 | Method for treatment of prostate cancer and diagnosing of patients benefiting from the same | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2011-01-12 | — | — | EP | disclosed |
| US-20100215638-A1 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215638-A1 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD | ERG, KLK3, ESRRB | HDAC1 2212/4885HDAC8 934/4885HDAC10 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.